NASDAQ:CDNA
CareDx Stock News
$8.28
+0.430 (+5.48%)
At Close: Apr 17, 2024
How CareDx (CDNA) Stock Stands Out in a Strong Industry
09:41am, Monday, 01'st Apr 2024
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
10:22pm, Wednesday, 28'th Feb 2024
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
08:01pm, Wednesday, 28'th Feb 2024
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Stree
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
10:21am, Monday, 26'th Feb 2024
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
11:16am, Friday, 08'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positiv
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
11:17am, Wednesday, 22'nd Nov 2023
The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript
08:13pm, Wednesday, 08'th Nov 2023
CareDx, Inc (NASDAQ:CDNA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
09:01am, Monday, 06'th Nov 2023
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
10:42am, Wednesday, 09'th Aug 2023
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
07:42pm, Tuesday, 08'th Aug 2023
CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13 per share a year ago.
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
10:15am, Monday, 10'th Jul 2023
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Why Shares of CareDx Are Jumping Friday
12:26pm, Friday, 07'th Jul 2023
CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.
CareDx to Participate in Upcoming Investor Conferences
07:00am, Thursday, 01'st Jun 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val
CareDx to Report First Quarter 2023 Financial Results
07:01am, Monday, 08'th May 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
CareDx, Inc. (CDNA) Q4 2022 Results Earnings Call Transcript
10:37pm, Monday, 27'th Feb 2023
CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Part